Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares dropped 4.1% on Thursday . The company traded as low as $160.40 and last traded at $165.51, with a volume of 383,901 shares changing hands. The stock had previously closed at $172.59.

ICPT has been the topic of a number of recent analyst reports. Oppenheimer Holdings Inc. reissued a “buy” rating and set a $309.00 price target on shares of Intercept Pharmaceuticals in a research report on Saturday, April 9th. Needham & Company LLC reissued a “buy” rating and set a $350.00 price target on shares of Intercept Pharmaceuticals in a research report on Saturday, April 9th. Cowen and Company reissued a “buy” rating and set a $212.00 price target on shares of Intercept Pharmaceuticals in a research report on Saturday, April 9th. BMO Capital Markets reissued a “buy” rating and set a $239.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, May 3rd. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, May 3rd. Four analysts have rated the stock with a sell rating, six have given a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $180.83.

The stock’s 50 day moving average is $152.43 and its 200 day moving average is $136.54. The company’s market capitalization is $3.99 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($3.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.69) by $0.55. The company had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $1.72 million. During the same period last year, the business earned ($1.99) earnings per share. The company’s quarterly revenue was up 1140.4% compared to the same quarter last year. Equities research analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.42) EPS for the current year.

In related news, insider Lisa Bright sold 251 shares of the firm’s stock in a transaction on Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total value of $34,512.50. Following the completion of the transaction, the insider now directly owns 18,855 shares of the company’s stock, valued at $2,592,562.50. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Mark Pruzanski sold 714 shares of the firm’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $145.11, for a total transaction of $103,608.54. The disclosure for this sale can be found here.

A number of hedge funds recently modified their holdings of ICPT. BlackRock Advisors LLC increased its stake in shares of Intercept Pharmaceuticals by 5.4% in the fourth quarter. BlackRock Advisors LLC now owns 125,274 shares of the biopharmaceutical company’s stock worth $18,710,000 after buying an additional 6,461 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Intercept Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,610 shares of the biopharmaceutical company’s stock worth $5,468,000 after buying an additional 578 shares in the last quarter. New York State Common Retirement Fund increased its stake in shares of Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock worth $5,586,000 after buying an additional 800 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock worth $2,367,000 after buying an additional 109 shares in the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.